Zydus Life gets final USFDA approval to manufacture, market ulcer drug, ET HealthWorld

New Delhi: Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market sucralfate tablets used in the treatment and prevention of ulcers in the intestines.

The approval granted by the US Food and Drug Administration (USFDA) is to manufacture and market Sucralfate Tablets of strength 1 gram, Zydus Lifesciences said in a regulatory filing. The drug will be manufactured at the group’s topical manufacturing facility at SEZ, Ahmedabad, it added.

Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury, and thus helps ulcers heal more quickly, the company said.

Sucralfate tablets 1 gram had annual sales of USD 84 million in the US, it said citing IQVIA MAT February 2023 data.

  • Published On May 5, 2023 at 01:40 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App

Paid Prime Membership on Primevideo.com

Source link

Leave a Comment

New Report